PhD fellow and MD Simer Bains presents data on aspirin treatment and colorectal cancer at the 2015 ASCO Conference

The 2015 American Society of Clinical Oncology (ASCO) Meeting took place in Chicago on May 29 - June 2. This Annual Meeting brings together 30,000 oncology professionals from around the world. On May 30 NCMM PhD fellow Simer Bains gave an oral presentation entitled "Impact of aspirin as secondary prevention in an unselected cohort of 25 644 patients with colorectal cancer: A population-based study".

Simer Bains presented data from an observational study revealing that patients with colorectal cancer that have been treated with aspirin live significantly longer than patients that did not use aspirin. The data in this study came from the Norwegian Cancer Registry and the Norwegian Prescription Database and included all patients diagnosed with colorectal cancer in Norway in the period 2004-2011.

Professor David Kerr, University of Oxford, commented on the aspirin registry study presented at ASCO, 2015 in a view-article in Medscape published on 22 May. 

Furthermore, a new multicenter study has recently been initiated focusing on aspirin effects on patients suffering from colorectal cancer that have also surgically removed liver metastases. This study is a collaboration with Oslo University Hopsital (Bjørn Atle Bjørnbeth) as well as with colleagues in Stavanger, Bergen, Trondheim and Tromsø.

Published June 1, 2015 12:50 PM - Last modified Jan. 1, 2017 7:13 PM